Journey Strategic Wealth’s Madrigal Pharmaceuticals MDGL Stock Holding History

Journey Strategic Wealth’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.72M	Hold	12,829	–	–	0.17%	41
2025 Q4	$7.47M	Buy	12,829 +1	+0%	+$511	0.2%	38
2025 Q3	$5.88M	Sell	12,828 -250	-2%	-$93.3K	0.17%	44
2025 Q2	$3.96M	Hold	13,078	–	–	0.13%	59
2025 Q1	$4.33M	Hold	13,078	–	–	0.15%	48
2024 Q4	$4.04M	Sell	13,078 -250	-2%	-$70.3K	0.15%	43
2024 Q3	$2.83M	Buy	13,328 +3	+0%	+$767	0.1%	51
2024 Q2	$3.73M	Buy	13,325 +5	+0%	+$1.19K	0.16%	32
2024 Q1	$3.56M	Hold	13,320	–	–	0.16%	31
2023 Q4	$3.08M	Hold	13,320	–	–	0.15%	29
2023 Q3	$1.95M	Sell	13,320 -31	-0.2%	-$5.83K	0.09%	35
2023 Q2	$3.08M	Sell	13,351 -503	-4%	-$136K	0.14%	29
2023 Q1	$3.36M	Sell	13,854 -7	-0.1%	-$1.91K	0.35%	23
2022 Q4	$4.02M	Buy	13,861 +36	+0.3%	+$3.52K	0.47%	20
2022 Q3	$898K	Buy	13,825 +5	+0%	+$347	0.12%	46
2022 Q2	$989K	Hold	13,820	–	–	0.13%	41
2022 Q1	$1.36M	Hold	13,820	–	–	0.15%	20
2021 Q4	$1.17M	Buy	+13,820	New	+$1.14M	0.12%	38

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Journey Strategic Wealth's MDGL Position: Q1 2026 in Review

Journey Strategic Wealth held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 12,829 shares worth $6.72M. The position accounts for 0.17% of the portfolio, ranked #41.

Journey Strategic Wealth first reported a position in MDGL in Q4 2021 and has held it in 18 quarters since. The position peaked at $7.47M in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Journey Strategic Wealth held 12,829 shares of Madrigal Pharmaceuticals worth $6.72M as of Q1 2026.
Journey Strategic Wealth left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
Madrigal Pharmaceuticals made up 0.17% of Journey Strategic Wealth's portfolio in Q1 2026, its #41 holding.
Journey Strategic Wealth first reported a position in Madrigal Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Journey Strategic Wealth's Madrigal Pharmaceuticals position peaked at $7.47M in Q4 2025.
380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.